PMID- 31431809
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220409
IS  - 1756-2856 (Print)
IS  - 1756-2864 (Electronic)
IS  - 1756-2856 (Linking)
VI  - 12
DP  - 2019
TI  - Therapeutic effect on experimental acute cerebral infarction is enhanced after 
      nanoceria labeling of human umbilical cord mesenchymal stem cells.
PG  - 1756286419859725
LID - 10.1177/1756286419859725 [doi]
LID - 1756286419859725
AB  - BACKGROUND: Therapeutic applications of stem cells, especially mesenchymal stem 
      cells, were once regarded as a promising therapy for mitigating acute cerebral 
      infarction. Unfortunately, all the stem cell clinical trials have been futile. A 
      new stroke therapeutic strategy of combining stem cells with nanotechnology has 
      recently gained significant attention. The objective of this study was to 
      evaluate the application of cerium oxide nanoparticle (nanoceria)-labeled human 
      umbilical cord mesenchymal stem cells (HucMSCs) for stroke therapy. METHODS: In 
      our study, cerium oxide nanoparticles were precovered with hyaluronic acid before 
      labeling HucMSCs and the synergistic effects from both HucMSCs and cerium oxide 
      nanoparticles were analyzed in in vivo and in vitro experiments. RESULTS: The 
      nanoceria-labeled HucMSCs combined advantages from both sides, including the 
      capacity for inflammatory modulation of HucMSCs and the antioxidant effects of 
      nanoceria. Compared with either HucMSCs or nanoceria individually, 
      nanoceria-labeled HucMSCs exerted significantly enhanced capacities after gaining 
      combined antioxidant and anti-inflammatory effects. CONCLUSION: Our findings 
      suggest a novel strategy with effective and well-tolerated applications of stem 
      cells for acute cerebral infarction therapy after modification of cells with 
      nanomaterials.
FAU - Zuo, Lian
AU  - Zuo L
AD  - Department of Neurology, East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Feng, Qishuai
AU  - Feng Q
AD  - Department of Neurology, East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Han, Yingying
AU  - Han Y
AD  - Department of Neurology, East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Chen, Mengwei
AU  - Chen M
AD  - East Hospital, The Institute for Biomedical Engineering and Nano Science, Tongji 
      University School of Medicine, Shanghai, China.
FAU - Guo, Mengruo
AU  - Guo M
AD  - Department of Neurology, East Hospital, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Liu, Zhongmin
AU  - Liu Z
AD  - Department of Intensive Care Center, East Hospital, Tongji University School of 
      Medicine, Shanghai, 200120, China.
FAU - Cheng, Yu
AU  - Cheng Y
AD  - East Hospital; The Institute for Biomedical Engineering & Nano Science, Tongji 
      University School of Medicine, Shanghai, 200120, China.
FAU - Li, Gang
AU  - Li G
AUID- ORCID: 0000-0003-1737-0107
AD  - Department of Neurology,East Hospital, Tongji University School of Medicine, 
      Shanghai, 200120, China.
LA  - eng
PT  - Journal Article
DEP - 20190730
PL  - England
TA  - Ther Adv Neurol Disord
JT  - Therapeutic advances in neurological disorders
JID - 101480242
PMC - PMC6685115
OTO - NOTNLM
OT  - acute cerebral infarction
OT  - anti-inflammatory
OT  - antioxidant
OT  - human umbilical cord mesenchymal stem cells
OT  - nanoceria
COIS- Conflict of interest statement: The authors declare that there is no conflict of 
      interest.
EDAT- 2019/08/23 06:00
MHDA- 2019/08/23 06:01
PMCR- 2019/07/30
CRDT- 2019/08/22 06:00
PHST- 2019/03/31 00:00 [received]
PHST- 2019/06/03 00:00 [accepted]
PHST- 2019/08/22 06:00 [entrez]
PHST- 2019/08/23 06:00 [pubmed]
PHST- 2019/08/23 06:01 [medline]
PHST- 2019/07/30 00:00 [pmc-release]
AID - 10.1177_1756286419859725 [pii]
AID - 10.1177/1756286419859725 [doi]
PST - epublish
SO  - Ther Adv Neurol Disord. 2019 Jul 30;12:1756286419859725. doi: 
      10.1177/1756286419859725. eCollection 2019.